Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117
https://www.facingourrisk.org/research-clinical-trials/study/159/treating-advanced-solid-tumors-in-people-with-inherited-pten-mutations-using-the-investigational-drug-tas-117
Clinicaltrials.gov identifier:
NCT04770246 (https://clinicaltrials.gov/show/NCT04770246)
People with advanced cancer and an inherited PTEN mutation
Study Contact Information:
For additional information, please contact:
Osamu Takahashi, MD, PhD by phone: 609-250-7336 or by email at: [email protected]
About the Study
This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors). NOTE: this study is no longer enrolling people.
This Study is Open To:
NOTE: this study is no longer enrolling people.
This Study is Not Open To:
NOTE: this study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.